HK1246689A1 - 溴莫尼定和噻嗎洛爾的固定劑量組合 - Google Patents

溴莫尼定和噻嗎洛爾的固定劑量組合

Info

Publication number
HK1246689A1
HK1246689A1 HK18106462.6A HK18106462A HK1246689A1 HK 1246689 A1 HK1246689 A1 HK 1246689A1 HK 18106462 A HK18106462 A HK 18106462A HK 1246689 A1 HK1246689 A1 HK 1246689A1
Authority
HK
Hong Kong
Prior art keywords
bromonidine
timolol
fixed dose
dose combination
combination
Prior art date
Application number
HK18106462.6A
Other languages
English (en)
Inventor
J‧焦
張金明
A‧V‧戈雷
R‧S‧格雷厄姆
R‧S‧喬丹
S‧尼爾萬南
C‧P‧普亞拉
沈潔
K‧S‧瓦納
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1246689A1 publication Critical patent/HK1246689A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18106462.6A 2015-03-19 2018-05-18 溴莫尼定和噻嗎洛爾的固定劑量組合 HK1246689A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562135320P 2015-03-19 2015-03-19
PCT/US2016/022874 WO2016149498A1 (en) 2015-03-19 2016-03-17 Fixed dose combination of bromonidine and timolol

Publications (1)

Publication Number Publication Date
HK1246689A1 true HK1246689A1 (zh) 2018-09-14

Family

ID=55640942

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106462.6A HK1246689A1 (zh) 2015-03-19 2018-05-18 溴莫尼定和噻嗎洛爾的固定劑量組合

Country Status (9)

Country Link
US (2) US20180078500A1 (zh)
EP (2) EP3270892B1 (zh)
JP (3) JP7199146B2 (zh)
KR (1) KR20170129823A (zh)
CN (1) CN107427460A (zh)
AU (3) AU2016233125A1 (zh)
CA (1) CA2977825A1 (zh)
HK (1) HK1246689A1 (zh)
WO (1) WO2016149498A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
JP6603785B2 (ja) * 2017-12-08 2019-11-06 千寿製薬株式会社 水溶性高分子を含む水性液剤
JP7378959B2 (ja) * 2018-05-11 2023-11-14 千寿製薬株式会社 眼科用組成物
US20210220515A1 (en) * 2018-05-25 2021-07-22 Eyebright Medical Technology (Beijing) Co., Ltd. Viscoelastic agent material
GR1010024B (el) * 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92351A (en) * 1988-11-29 1994-02-27 Allergan Inc Irvine Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt
CA2402405C (en) * 2000-07-14 2008-02-12 Allergan Sales, Inc. Compositions containing alpha-2-adrenergic agonist components
MXPA02012206A (es) * 2000-07-14 2003-06-04 Allergan Inc Composiciones que contienen componentes terapeuticamente activos que tienen solubilidad mejorada.
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
KR20070104884A (ko) 2004-11-24 2007-10-29 메드포인트 헬쓰케어 인크. 아젤라스틴을 포함하는 조성물 및 이의 사용 방법
US20070238732A1 (en) 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
US20130116254A1 (en) 2009-12-22 2013-05-09 Allergan, Inc. Compositions and methods for lowering intraocular pressure
CA2807084C (en) * 2010-07-29 2018-05-22 Allergan, Inc. Preservative free brimonidine and timolol solutions
CA2821969A1 (en) 2010-12-21 2012-06-28 Recopharma Ab Tear substitutes
ES2818073T3 (es) * 2013-12-24 2021-04-09 Sentiss Pharma Private Ltd Solución oftálmica de tartrato de brimonidina tópica
US20160331746A1 (en) * 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake

Also Published As

Publication number Publication date
EP3270892A1 (en) 2018-01-24
EP3270892B1 (en) 2024-04-10
AU2021203665A1 (en) 2021-09-02
WO2016149498A1 (en) 2016-09-22
CA2977825A1 (en) 2016-09-22
US20180078500A1 (en) 2018-03-22
AU2023208076A1 (en) 2023-08-10
EP4420726A2 (en) 2024-08-28
JP2018508545A (ja) 2018-03-29
KR20170129823A (ko) 2017-11-27
JP2021102626A (ja) 2021-07-15
AU2016233125A1 (en) 2017-09-14
JP2023086773A (ja) 2023-06-22
JP7199146B2 (ja) 2023-01-05
US20220370346A1 (en) 2022-11-24
CN107427460A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
IL287437A (en) Flavociclib solid dosage forms
HK1247614A1 (zh) 治療化合物及其用途
IL258931A (en) Medicinal compounds and methods
HK1258062A1 (zh) 給予惡拉戈利的方法
HK1232137A1 (zh) 治療化合物和組合物
IL282482A (en) Variants of protoxin-II and methods of use
ZA201902090B (en) Combination treatments comprising administration of imidazopyrazinones
HK1248697A1 (zh) 治療化合物及其用途
HK1246689A1 (zh) 溴莫尼定和噻嗎洛爾的固定劑量組合
ZA201802256B (en) Compounds and therapeutic uses thereof
IL285882A (en) Medicinal uses for l–4–chlorokynurenine
HK1250476A1 (zh) 原毒素-ii變體及使用方法
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
GB201617064D0 (en) Compounds and their therapeutic use
PL3081228T3 (pl) Iryzyna do leczenia i zapobiegania osteoporozie
GB201406172D0 (en) Therapy and pharmaceutical composition
HK1258056A1 (zh) 治療性化合物和其使用方法
GB201418809D0 (en) Therapeutic agents and uses thereof
PL3341481T3 (pl) Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne
GB201519644D0 (en) Therapy and pharmaceutical composition